Bluebird Bio Beats Investor Suit Over FDA Cancer Warning

By Sydney Price · May 27, 2025, 10:47 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. has beaten a shareholder suit accusing it of misleading investors about the likelihood of the U.S. Food and Drug Administration's decision requiring a "black box...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Recent Articles By Sydney

May 28, 2025
Mallinckrodt Investors Get Initial OK For $5.5M Settlement
May 20, 2025
Cancer Drug Co. Beats Investor Suit Over FDA Rejection
May 16, 2025
Biotech Co. Hit With Investor Suits Over Cancer Drug Launch
May 14, 2025
Integra Brass Face Investor Suit Over FDA Compliance Lapses
May 06, 2025
Trump Orders FDA To Speed Up Drug Plant Approvals
April 23, 2025
GoodRx Beats Investor Suit Over Kroger-Linked Biz
April 22, 2025
Tivity Health Denied Win In Suit Over Nutrisystem Buy
April 17, 2025
Zenas BioPharma Faces Investor Suit Over Post-IPO Plunge
April 16, 2025
DexCom Execs Sued For Allegedly Misleading Growth Claims
April 11, 2025
Dentsply Brass Face Investor Suit Over Alleged Dental Injuries